Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and efficacy of OrienX010 in unresectable malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OrienX010

Snippet

Sponsor: OrienGene Biotechnology Ltd. | Conditions: Melanoma (Skin) | Phase 2 | Status: UNKNOWN